고칼륨혈증 치료제 시장 규모, 점유율 및 동향 분석 보고서 : 약물 클래스별, 유통 채널별, 지역별, 부문 예측(2025-2033년)

Hyperkalemia Drugs Market Summary

The global hyperkalemia drugs market size was estimated at USD 1.23 billion in 2024 and is projected to reach USD 3.87 billion by 2033, growing at a CAGR of 13.8% from 2025 to 2033. The market growth is primarily driven by an aging population, increasing prevalence of chronic diseases like chronic kidney disease (CKD) and heart failure, and comorbidities such as diabetes.

The increasing prevalence of chronic kidney disease (CKD), heart failure, diabetes, and other medical conditions that contribute to elevated potassium levels in the blood is driving demand for effective hyperkalemia treatments. For instance, approximately 589 million adults aged 20-79 were reported to have diabetes globally. Projections indicated this figure would rise to 853 million by 2050. Notably, over 81% of affected adults resided in low and middle-income countries. Pharmaceutical companies focus on developing and delivering innovative therapeutic solutions to address this condition. In September 2025, AstraZeneca Pharma India received approval from the Subject Expert Committee(SEC), operating under the Central Drug Standard Control Organisation (CDSCO), to conduct a Phase-IV clinical trial of Sodium Zirconium Cyclosilicate (Lokelma) powder for oral suspension used to treat hyperkalemia in India. This trial will evaluate safety and efficacy for managing elevated potassium levels in adult patients, addressing critical cardiovascular and renal health needs in the region.

Aging global population, marked by a growing elderly segment, faces increased vulnerability to chronic conditions such as cardiovascular disease, chronic kidney disease, and diabetes, which elevate hyperkalemia risk. This is expected to drive the demand for hyperkalemia drugs, fostering pharmaceutical innovation and expanded treatment options. Advances in oral potassium binders and improved diagnostic capabilities support better management, while strategic collaborations and market expansion enhance drug accessibility worldwide.

Global Hyperkalemia Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hyperkalemia drugs market report based on drug class, distribution channel, and region:

• Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
• Novel Oral Potassium Binders
• Traditional Cation-Exchange Resins
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Distribution Channel
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug Class Outlook
  • 2.2.2. Distribution Channel Outlook
  • 2.2.3. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Hyperkalemia Drugs Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Hyperkalemia drugs Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. Hyperkalemia Drugs Market: Pipeline Analysis

Chapter 4. Hyperkalemia Drugs Market: Drug Class Estimates & Trend Analysis

• 4.1. Drug Class Segment Dashboard
• 4.2. Hyperkalemia Drugs Market: Drug Class Movement Analysis
• 4.3. Global Hyperkalemia Drugs Market Size & Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
• 4.4. Novel Oral Potassium Binders
  • 4.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.5. Traditional Cation-Exchange Resins
  • 4.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 4.6. Others
  • 4.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Hyperkalemia Drugs Market: Distribution Channel Estimates & Trend Analysis

• 5.1. Distribution Channel Segment Dashboard
• 5.2. Hyperkalemia Drugs Market: Distribution Channel Movement Analysis
• 5.3. Global Hyperkalemia Drugs Market Size & Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
• 5.4. Hospital Pharmacies
  • 5.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.5. Retail Pharmacies
  • 5.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
• 5.6. Online Pharmacies
  • 5.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Hyperkalemia Drugs Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Dashboard
• 6.2. Regional Market Share Analysis, 2024 & 2033
• 6.3. Hyperkalemia Drugs Market by Region: Key Takeaways
• 6.4. North America
  • 6.4.1. U.S.
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.2. Canada
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.3. Mexico
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 6.5. Europe
  • 6.5.1. UK
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.2. Germany
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.3. France
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.4. Italy
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.5. Spain
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.6. Norway
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.7. Sweden
    • 6.5.7.1. Key country dynamics
    • 6.5.7.2. Regulatory framework/ reimbursement structure
    • 6.5.7.3. Competitive scenario
    • 6.5.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.5.8. Denmark
    • 6.5.8.1. Key country dynamics
    • 6.5.8.2. Regulatory framework/ reimbursement structure
    • 6.5.8.3. Competitive scenario
    • 6.5.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Japan
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.2. China
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.3. India
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.4. Australia
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/ reimbursement structure
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.6.6. Thailand
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/ reimbursement structure
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 6.7. Latin America
  • 6.7.1. Brazil
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.7.2. Argentina
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 6.8. MEA
  • 6.8.1. South Africa
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.8.2. Saudi Arabia
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.8.3. UAE
    • 6.8.3.1. Key country dynamics
    • 6.8.3.2. Regulatory framework/ reimbursement structure
    • 6.8.3.3. Competitive scenario
    • 6.8.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.8.4. Kuwait
    • 6.8.4.1. Key country dynamics
    • 6.8.4.2. Regulatory framework/ reimbursement structure
    • 6.8.4.3. Competitive scenario
    • 6.8.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key company heat map analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. AstraZeneca plc
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. CSL Vifor (Vifor Pharma AG)
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Sanofi
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Kowa Company, Ltd.
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. KVK-Tech, Inc.
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Fresenius Kabi AG
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Novo Nordisk A/S
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives